# Patient-Trial Match Report

*Generated: 2026-01-05 06:56:17*

## Patient Profile

- **Age**: 61
- **Sex**: Male
- **Cancer Type**: colorectal cancer
- **Biomarkers**: KRAS G12C

**Clinical Description**:
> 61-year-old male with metastatic colorectal adenocarcinoma (sigmoid primary), KRAS G12C mutated, microsatellite stable (MSS). Initial FOLFOX + bevacizumab x12 cycles achieved stable disease. Second-line FOLFIRI + bevacizumab with progression after 4 cycles. Now seeking third-line options. Liver-dominant metastatic disease (6 lesions, largest 3.2cm). No peritoneal carcinomatosis. Good appetite, mild fatigue. CEA trending up (45 -> 82 over 2 months). Labs: mild transaminase elevation (AST 52, ALT 48), otherwise normal.

- **Location Preference**: United States

## Search Summary

- **Search terms used**: 12
- **Total trials evaluated**: 100
- **Excluded by fast filter**: 48
- **LLM scored**: 52

## ðŸŸ¢ HIGH Likelihood (17 trials)

### [NCT06412198](https://clinicaltrials.gov/study/NCT06412198)

**A Multicenter Phase 1b/2 Study of Adagrasib, Cetuximab, and Cemiplimab for Metastatic Colorectal Cancer Harboring KRAS G12C Mutations**

- **Sponsor**: M.D. Anderson Cancer Center
- **Phase**: Phase 1/Phase 2
- **Status**: Recruiting
- **Confidence**: 85%

**âœ“ Supporting Factors:**
- Histologically confirmed diagnosis of metastatic colorectal cancer with KRAS G12C mutation
- Patient has received prior chemotherapy (FOLFOX, FOLFIRI) for metastatic disease with progression
- ECOG status of 1
- Presence of measurable disease per RECIST 1.1
- MSS status confirmed
- No brain metastases

**? Uncertainties:**
- Laboratory values and organ function tests (e.g., creatinine clearance) are not explicitly provided

**Assessment:**
> The patient has an eligible cancer type (KRAS G12C mutated metastatic colorectal cancer) and has received multiple lines of prior chemotherapy, which aligns with the trial's focus on previously treated patients. The ECOG status and absence of brain metastases further support eligibility, although laboratory values are needed for final confirmation on organ function.

---

### [NCT04956640](https://clinicaltrials.gov/study/NCT04956640)

**A Phase 1/2 Study of LY3537982 in Patients With KRAS G12C-Mutant Advanced Solid Tumors**

- **Sponsor**: Eli Lilly and Company
- **Phase**: Phase 1/Phase 2
- **Status**: Recruiting
- **Confidence**: 85%

**âœ“ Supporting Factors:**
- Colorectal cancer matches the conditions studied in the trial.
- Patient has KRAS G12C mutation.
- ECOG status is 1, which is acceptable.

**? Uncertainties:**
- Need to verify adequate organ function based on lab tests.
- Patient's exact adherence to the requirement of having discontinued previous treatments is not explicitly confirmed.

**Assessment:**
> The patient's cancer type matches the trial conditions as the trial includes colorectal neoplasms. The patient has the required KRAS G12C mutation and has an appropriate ECOG status of 1. The patient is not treatment-naive and has previously received therapy which aligns with trial requirements for those having received prior treatments. Overall, confidence is high with minor uncertainties regarding organ function and treatment history.

---

### [NCT05410145](https://clinicaltrials.gov/study/NCT05410145)

**A Phase 1/2, Open Label, Dose-escalation, and Dose-expansion Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of D3S-001 Monotherapy or Combination Therapy in Subjects With Advanced Solid Tumors With a KRAS p.G12C Mutation**

- **Sponsor**: D3 Bio (Wuxi) Co., Ltd
- **Phase**: Phase 1/Phase 2
- **Status**: Recruiting
- **Confidence**: 85%

**âœ“ Supporting Factors:**
- Metastatic colorectal adenocarcinoma confirmed
- Documented KRAS G12C mutation
- ECOG performance status of 1
- Measurable disease with liver lesions
- No brain metastases

**? Uncertainties:**
- Organ function labs not fully confirmed as adequate
- No details on the washout periods for prior therapies

**Assessment:**
> The patient's cancer type matches the trial's indication for KRAS G12C mutation. The patient has prior treatments and is seeking third-line options, which aligns with the eligibility criteria for previously treated patients. The ECOG status and absence of brain metastases further support eligibility.

---

### [NCT05786924](https://clinicaltrials.gov/study/NCT05786924)

**A Phase 1/2, Open-label Study of Oral S241656 (BDTX-4933) as Monotherapy and in Combination With Other Anti-Cancer Therapies in Patients With KRAS, BRAF and Other Selected RAS/MAPK Mutation-Positive Malignancies**

- **Sponsor**: Institut de Recherches Internationales Servier
- **Phase**: Phase 1/Phase 2
- **Status**: Recruiting
- **Confidence**: 85%

**âœ“ Supporting Factors:**
- Patient has colorectal cancer, which is included in the trial conditions studied.
- Patient's cancer is KRAS G12C mutated, which is relevant for the trial.
- ECOG status of 1 is acceptable for trial admission.
- No brain metastases reported.

**? Uncertainties:**
- The patient's organ function labs confirm mild abnormalities (AST 52, ALT 48), but it's unclear if this meets the trial's requirement for adequate organ function.

**Assessment:**
> The patient's colorectal cancer diagnosis matches the trial's inclusion criteria, and he is a previously treated patient seeking third-line options, which aligns with the trial's focus. His KRAS G12C mutation supports his eligibility. Minor uncertainty exists regarding organ function due to lab results.

---

### [NCT06244771](https://clinicaltrials.gov/study/NCT06244771)

**An Open-Label, Phase 1/2 Dose Escalation, Dose Expansion and Cohort Expansion Study Evaluating the Safety, PK and Clinical Activity of FMC-376 in Participants With KRAS G12C Mutated Locally Advanced Unresectable or Metastatic Solid Tumors**

- **Sponsor**: Frontier Medicines Corporation
- **Phase**: Phase 1/Phase 2
- **Status**: Recruiting
- **Confidence**: 85%

**âœ“ Supporting Factors:**
- Patient has KRAS G12C mutation as required by the trial
- ECOG performance status is 1, which meets the trial requirement
- Patient has received prior therapies (FOLFOX, bevacizumab, FOLFIRI) and is seeking third-line options, in line with the trial criteria for previously treated patients
- No brain metastases present, which aligns with eligibility criteria

**? Uncertainties:**
- Hematological, renal, and hepatic function status is unclear due to missing specific lab results
- No explicit information about any clinically significant toxicity from prior therapies

**Assessment:**
> The patient's cancer type matches the trial indication as they have metastatic colorectal cancer with KRAS G12C mutation. The patient is also previously treated, seeking third-line therapy, which aligns with the trial requirements. While some aspects of organ function and prior toxicities are uncertain, they do not negate overall eligibility.

---

### [NCT05067283](https://clinicaltrials.gov/study/NCT05067283)

**A Phase 1, Open-label, Multicenter Study to Assess Safety, Tolerability, PK, and Efficacy of MK-1084 as Monotherapy and as Part of Various Combination Therapies in Participants With KRAS G12C Mutant Advanced Solid Tumors**

- **Sponsor**: Merck Sharp & Dohme LLC
- **Phase**: Phase 1
- **Status**: Recruiting
- **Confidence**: 85%

**âœ“ Supporting Factors:**
- Patient has locally advanced unresectable or metastatic colorectal adenocarcinoma.
- Patient has histologically or blood-based confirmation of KRAS G12C mutation.
- Patient has received at least 1 line of therapy for systemic disease.

**Assessment:**
> The patient's cancer type matches the trial conditions as they have metastatic colorectal adenocarcinoma with the required KRAS G12C mutation. The patient has received prior systemic therapy, which aligns with the trial's requirement for previously treated patients.

---

### [NCT04511039](https://clinicaltrials.gov/study/NCT04511039)

**A Phase I Study of Trifluridine/ Tipiracil Plus the Poly (ADP) Ribose Polymerase Inhibitor Talazoparib in Advanced Cancers**

- **Sponsor**: Roswell Park Cancer Institute
- **Phase**: Phase 1
- **Status**: Recruiting
- **Confidence**: 85%

**âœ“ Supporting Factors:**
- Histologically confirmed metastatic colorectal adenocarcinoma
- Patient has received at least three prior lines of therapy with progression
- ECOG status is 1
- No brain metastases

**? Uncertainties:**
- Lab values related to hemoglobin, absolute neutrophil count, platelet count, creatinine, total bilirubin, AST/ALT levels, and albumin were not fully provided

**Assessment:**
> The patient's cancer type matches the trial's indication for metastatic colorectal adenocarcinoma and they have received multiple prior therapies. ECOG status is acceptable. However, several lab values are not provided which could impact eligibility.

---

### [NCT05746897](https://clinicaltrials.gov/study/NCT05746897)

**A Phase 1 Study to Investigate the Safety, Tolerability, Pharmacokinetics/Pharmacodynamics, and Antitumor Activity of NM1F as Monotherapy and in Combination With Pembrolizumab in Subjects With Locally Advanced/Metastatic Solid Tumors**

- **Sponsor**: Hefei TG ImmunoPharma Co., Ltd.
- **Phase**: Phase 1
- **Status**: Recruiting
- **Confidence**: 85%

**âœ“ Supporting Factors:**
- Age 61 is greater than 18 years
- Colorectal cancer is included in the conditions studied
- ECOG status is 1
- Patient has unresectable metastatic colorectal cancer
- Patient has at least 1 evaluable lesion
- Patient has a life expectancy greater than 3 months
- Patient has no evidence of brain metastases
- Patient has prior systemic therapies consistent with study requirements

**? Uncertainties:**
- Baseline organ function and laboratory data are not fully outlined
- Specifics on the patient's acceptable range for prior treatments based on the exclusion criteria

**Assessment:**
> The patient's cancer type of colorectal cancer matches the trial's conditions studied. The treatment line is appropriate, and the patient meets the major eligibility criteria regarding age, ECOG status, and lack of brain metastases. Some uncertainties regarding laboratory data exist, but they do not significantly affect the overall assessment of eligibility.

---

### [NCT06128551](https://clinicaltrials.gov/study/NCT06128551)

**Phase 1b, Multicenter, Open-Label, Dose Escalation and Dose Expansion Study of RMC-6291 in Combination with RMC-6236 in Participants with Advanced KRAS G12C Mutant Solid Tumors**

- **Sponsor**: Revolution Medicines, Inc.
- **Phase**: Phase 1
- **Status**: Recruiting
- **Confidence**: 85%

**âœ“ Supporting Factors:**
- Patient has KRAS G12C mutated colorectal cancer, which is included in the trial conditions studied.
- Patient is previously treated, having received FOLFOX and FOLFIRI.
- ECOG status is 1, which is acceptable.

**? Uncertainties:**
- Adequate organ function criteria are met, but specific lab values for organ function (e.g., kidney function) are not provided.
- Patient's exact history of other minor procedures is not specified.

**Assessment:**
> The patient has a suitable cancer type (colorectal cancer with KRAS G12C mutation) and is previously treated, aligning with the trial requirements. Minor uncertainties regarding specific organ function lab values exist, but overall, the patient meets most eligibility criteria.

---

### [NCT06026410](https://clinicaltrials.gov/study/NCT06026410)

**Phase 1, First-in-Human, Multicenter, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of KO-2806 When Administered as Monotherapy and in Combination Therapy in Adult Patients With Advanced Solid Tumors**

- **Sponsor**: Kura Oncology, Inc.
- **Phase**: Phase 1
- **Status**: Recruiting
- **Confidence**: 85%

**âœ“ Supporting Factors:**
- Patient has metastatic colorectal cancer (CRC), which matches the trial conditions studied.
- Patient has KRAS G12C mutation, which is required for the trial's combination treatment.
- Patient's age is 61, which is above 18, meeting the age criteria.
- Patient has an ECOG status of 1, which is acceptable.
- No brain metastases reported.

**âœ— Potential Conflicts:**
- Patient has received prior therapies (FOLFOX, bevacizumab, FOLFIRI) which aligns with the requirement for previously treated patients in this trial.

**? Uncertainties:**
- Liver function is uncertain (mild transaminase elevation is noted, but overall function wasn't specified).
- No specific details about other organ function, renal, or endocrine health provided.

**Assessment:**
> The patient's cancer type (colorectal cancer) matches the indications in the trial. He has a KRAS G12C mutation, qualifying him for the combination treatment arm. He has received prior treatment lines, which aligns with the trial's criteria for previously treated patients. The only uncertainties relate to liver function and general organ health.

---

### [NCT06447662](https://clinicaltrials.gov/study/NCT06447662)

**A Phase 1 Open-Label Study of PF-07934040 as a Single Agent and in Combination With Other Targeted Agents in Participants With Advanced Solid Tumors Harboring Mutations in the KRAS Gene**

- **Sponsor**: Pfizer
- **Phase**: Phase 1
- **Status**: Recruiting
- **Confidence**: 85%

**âœ“ Supporting Factors:**
- Diagnosis of colorectal cancer
- KRAS G12C mutation confirmed
- ECOG PS of 1
- Progressed on prior systemic treatment regimens for mCRC

**Assessment:**
> The patient's colorectal cancer diagnosis aligns with the trial's focus on colorectal neoplasms, and he has the required KRAS G12C mutation. He is not treatment-naive, having received multiple prior therapies, which is acceptable for this trial as it is intended for previously treated patients. The patient's ECOG status meets the trial criteria, indicating good performance status.

---

### [NCT06720987](https://clinicaltrials.gov/study/NCT06720987)

**A Phase 1/1b, Open-label, Multicenter, Dose Escalation and Dose Optimization Study Evaluating the Safety, Tolerability, Pharmacokinetics and Efficacy of KQB365 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies With KRAS G12S or G12C Mutations**

- **Sponsor**: Kumquat Biosciences Inc.
- **Phase**: Phase 1
- **Status**: Recruiting
- **Confidence**: 85%

**âœ“ Supporting Factors:**
- Histologically confirmed diagnosis of colorectal cancer
- KRAS G12C mutation
- Unresectable or metastatic disease
- No available treatment with curative intent
- ECOG status is 1

**? Uncertainties:**
- Adequate organ function (mild transaminase elevation noted, further assessment needed)

**Assessment:**
> The patient's colorectal cancer with KRAS G12C mutation aligns with the trial's inclusion criteria focusing on colorectal adenocarcinoma with specific KRAS mutations. The patient has received prior therapies, which fits with the trial being for previously treated patients. The only uncertainty is related to the assessment of organ function, but overall, the patient meets the critical criteria for eligibility.

---

### [NCT06917079](https://clinicaltrials.gov/study/NCT06917079)

**A Phase 1a/1b Open-Label Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of BBO-11818 in Subjects With Advanced KRAS Mutant Cancers**

- **Sponsor**: TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)
- **Phase**: Phase 1
- **Status**: Recruiting
- **Confidence**: 85%

**âœ“ Supporting Factors:**
- Patient has metastatic colorectal cancer, which matches the trial's conditions studied.
- Patient has KRAS G12C mutation, which is included in the trial's biomarker criteria.
- ECOG status is 1, which meets the trial's performance status requirement.

**? Uncertainties:**
- Mild transaminase elevation (AST 52, ALT 48) could raise concerns about organ function but data is insufficient to determine if it meets specific eligibility thresholds.

**Assessment:**
> The patient's cancer type is colorectal cancer, matching the trial criteria. The patient also has the required KRAS G12C mutation and meets ECOG performance status criteria. There are minor uncertainties regarding liver function tests, but these do not significantly impact eligibility.

---

### [NCT04929223](https://clinicaltrials.gov/study/NCT04929223)

**A Phase I/Ib Global, Multicenter, Open-label Umbrella Study Evaluating the Safety and Efficacy of Targeted Therapies in Subpopulations of Patients With Metastatic Colorectal Cancer (INTRINSIC)**

- **Sponsor**: Hoffmann-La Roche
- **Phase**: Phase 1
- **Status**: Recruiting
- **Confidence**: 84%

**âœ“ Supporting Factors:**
- Age is 61, which is above 18 years
- ECOG status is 1
- Patient has metastatic colorectal adenocarcinoma
- Patient has prior systemic therapies including FOLFOX and FOLFIRI
- Patient's cancer has the KRAS G12C mutation

**? Uncertainties:**
- Adequate hematologic and organ function details are not provided
- Life expectancy determination is not explicitly mentioned

**Assessment:**
> The patient's cancer type matches the trial's indication for metastatic colorectal cancer, and they have the required KRAS G12C mutation. The patient is also previously treated, which aligns with the trial's requirements for eligible participants. There are some uncertainties regarding organ function and life expectancy, but overall, the patient likely meets most criteria.

---

### [NCT05863195](https://clinicaltrials.gov/study/NCT05863195)

**A Randomized Phase III Study of Systemic Therapy With or Without Hepatic Arterial Infusion for Unresectable Colorectal Liver Metastases: The PUMP Trial**

- **Sponsor**: ECOG-ACRIN Cancer Research Group
- **Phase**: Phase 3
- **Status**: Recruiting
- **Confidence**: 80%

**âœ“ Supporting Factors:**
- Patient has colorectal cancer, which matches the trial's conditions studied.
- Patient is 61 years old, which meets the eligibility age requirement (>= 18 years).
- Patient has an ECOG status of 1, which is acceptable for enrollment.
- Patient has received multiple prior lines of therapy, which meets the trial's requirement for previously treated patients.
- Patient has liver-dominant metastatic disease with no peritoneal carcinomatosis.
- Patient's biomarkers include KRAS G12C, which is specified in the trial's inclusion criteria.

**? Uncertainties:**
- Patient's organ function labs are not provided for leukocytes, absolute neutrophil count, platelets, total bilirubin, AST, ALT, and creatinine.
- Confirmation of full compliance with imaging requirements for liver unresectability is unclear.

**Assessment:**
> The patient's colorectal cancer type aligns well with the trial's focus on unresectable liver metastatic colorectal cancer. While the patient is previously treated, the trial is designed for previously treated patients, thus aligning in terms of treatment line. However, some organ function lab results are missing, creating uncertainty that affects confidence.

---

### [NCT06607185](https://clinicaltrials.gov/study/NCT06607185)

**A Phase 1a/1b Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors**

- **Sponsor**: Eli Lilly and Company
- **Phase**: Phase 1
- **Status**: Recruiting
- **Confidence**: 80%

**âœ“ Supporting Factors:**
- Patient has a histologically proven diagnosis of metastatic colorectal adenocarcinoma.
- Patient has KRAS G12C mutation.
- Patient has an ECOG performance status of 1.
- Patient has measurable disease per RECIST 1.1 (liver lesions).

**? Uncertainties:**
- Mild transaminase elevation could be an unresolved toxicity; further confirmation needed if these levels are Grade 1 or higher.
- No information on other unresolved toxicities from prior therapies.

**Assessment:**
> The patient clearly matches the disease type (colorectal cancer) and has the required KRAS mutation. The patient's ECOG status and measurable disease meet trial criteria. While there are uncertainties regarding transaminase levels and potential unresolved toxicities, the overall profile suggests a strong likelihood of eligibility.

---

### [NCT06896162](https://clinicaltrials.gov/study/NCT06896162)

**PROGRESS: Precision Oncology Using Genomic Reflexive Evaluations for Study Selection and Survival**

- **Sponsor**: UNC Lineberger Comprehensive Cancer Center
- **Phase**: Not Applicable
- **Status**: Recruiting
- **Confidence**: 75%

**âœ“ Supporting Factors:**
- Patient has a documented Stage IV solid tumor malignancy (colorectal cancer)
- ECOG status of 1 meets trial eligibility criteria (0-2)
- Patient has agreed to comply with study procedures

**? Uncertainties:**
- Lab values for organ function are partially reported; transaminase levels are slightly elevated but not clearly indicative of exclusion
- Details regarding whether a genomic tumor test has been ordered or not are not provided

**Assessment:**
> The patient meets the disease type requirement with colorectal cancer, which is included in the trial. The patient is not treatment-naive, having undergone multiple lines of therapy; however, the trial does not explicitly state that it excludes previously treated patients. The patient meets the ECOG requirement, but there are minor uncertainties regarding testing and lab values.

---

## Excluded (83 trials)

### Excluded by Fast Filter

| NCT ID | Reason |
|--------|--------|
| [NCT05239338](https://clinicaltrials.gov/study/NCT05239338) | Patient age 61 is above maximum age 49 |
| [NCT04130516](https://clinicaltrials.gov/study/NCT04130516) | Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers |
| [NCT04291105](https://clinicaltrials.gov/study/NCT04291105) | Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers |
| [NCT04302025](https://clinicaltrials.gov/study/NCT04302025) | Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers |
| [NCT04589845](https://clinicaltrials.gov/study/NCT04589845) | Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers |
| [NCT05254327](https://clinicaltrials.gov/study/NCT05254327) | Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers |
| [NCT05281471](https://clinicaltrials.gov/study/NCT05281471) | Trial requires female patients |
| [NCT05552755](https://clinicaltrials.gov/study/NCT05552755) | Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers |
| [NCT05638295](https://clinicaltrials.gov/study/NCT05638295) | Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers |
| [NCT05892068](https://clinicaltrials.gov/study/NCT05892068) | Trial requires female patients |
| [NCT05961709](https://clinicaltrials.gov/study/NCT05961709) | Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers |
| [NCT06050668](https://clinicaltrials.gov/study/NCT06050668) | Patient age 61 is below minimum age 65 |
| [NCT06050707](https://clinicaltrials.gov/study/NCT06050707) | Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers |
| [NCT06514794](https://clinicaltrials.gov/study/NCT06514794) | Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers |
| [NCT06588686](https://clinicaltrials.gov/study/NCT06588686) | Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers |
| [NCT06876363](https://clinicaltrials.gov/study/NCT06876363) | Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers |
| [NCT06881784](https://clinicaltrials.gov/study/NCT06881784) | Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers |
| [NCT02333604](https://clinicaltrials.gov/study/NCT02333604) | Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers |
| [NCT02775461](https://clinicaltrials.gov/study/NCT02775461) | Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers |
| [NCT03260491](https://clinicaltrials.gov/study/NCT03260491) | Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers |
| ... | *and 28 more* |

### Excluded by Eligibility Assessment

| NCT ID | Sponsor | Reason |
|--------|---------|--------|
| [NCT04624555](https://clinicaltrials.gov/study/NCT04624555) | Case Comprehensive C | Patient has stage IV colorectal cancer, which is excluded by the trial criteria. |
| [NCT06252649](https://clinicaltrials.gov/study/NCT06252649) | Amgen | Patient has previously received treatment (FOLFOX and FOLFIRI), but trial is for treatment-naive patients only. |
| [NCT05411718](https://clinicaltrials.gov/study/NCT05411718) | M.D. Anderson Cancer | Patient has colorectal cancer, but the trial specifically studies Lynch syndrome, which the patient does not have. |
| [NCT04421820](https://clinicaltrials.gov/study/NCT04421820) | Bold Therapeutics, I | Patient has received 2 prior lines of therapy, while the trial requires patients with 2 prior lines of therapy (one of which must be 5-FU based) to enter a specific arm (ARM VI) |
| [NCT05920356](https://clinicaltrials.gov/study/NCT05920356) | Amgen | Patient has colorectal cancer, while the trial is for non-squamous non-small cell lung cancer (NSCLC). |
| [NCT06265285](https://clinicaltrials.gov/study/NCT06265285) | Mayo Clinic | Patient has metastatic colorectal carcinoma which does not match the trial's focus on advanced esophageal, renal, or other specified cancers. |
| [NCT06695845](https://clinicaltrials.gov/study/NCT06695845) | Jazz Pharmaceuticals | Patient has a KRAS G12C mutation; trial excludes colorectal cancer participants with known KRAS mutations. |
| [NCT06710756](https://clinicaltrials.gov/study/NCT06710756) | Perspective Therapeu | Patient has received prior systemic therapy (FOLFOX, bevacizumab, FOLFIRI) whereas the trial may require treatment-naive patients. |
| [NCT01365169](https://clinicaltrials.gov/study/NCT01365169) | M.D. Anderson Cancer | Trial specific inclusion criteria state 'recurrent colorectal cancer' for Arm 1, but the patient is seeking third-line options, suggesting prior treatment may not meet trial standards for this phase. |
| [NCT06253871](https://clinicaltrials.gov/study/NCT06253871) | Iambic Therapeutics, | Patient has colorectal cancer, but the trial is focused on HER2 alterations, which the patient does not have. |
| [NCT06130254](https://clinicaltrials.gov/study/NCT06130254) | M.D. Anderson Cancer | Patient has colorectal cancer, but trial is studying advanced solid tumors, specifically focusing on gynecological, breast, pancreatic, and KEAP1 mutated non-small cell lung cancers. |
| [NCT06403436](https://clinicaltrials.gov/study/NCT06403436) | TOLREMO therapeutics | Patient has colorectal cancer and trial is for advanced solid tumors including KRAS G12C but not specifically mentioned for colorectal cancer. |
| [NCT06358430](https://clinicaltrials.gov/study/NCT06358430) | M.D. Anderson Cancer | Trial requires participants to have minimal residual disease (MRD), but patient has active metastatic disease. |
| [NCT06625983](https://clinicaltrials.gov/study/NCT06625983) | Massachusetts Genera | Patient has colorectal cancer, but trial is for average risk patients aged 45-75 overdue for CRC screening; patient is not average risk due to metastatic disease. |
| [NCT06248606](https://clinicaltrials.gov/study/NCT06248606) | Ryan Gentzler, MD | Patient has colorectal cancer while the trial is for non-small cell lung cancer (NSCLC). |
| [NCT06875310](https://clinicaltrials.gov/study/NCT06875310) | Mirati Therapeutics  | Trial studies non-squamous non-small cell lung cancer, but patient has colorectal cancer. |
| [NCT06343402](https://clinicaltrials.gov/study/NCT06343402) | TheRas, Inc., d/b/a  | Patient has colorectal cancer while trial is for non-small cell lung cancer |
| [NCT05630794](https://clinicaltrials.gov/study/NCT05630794) | National Cancer Inst | Patient has metastatic colorectal cancer while trial is studying chemoprevention in patients with familial adenomatous polyposis or those with recurrent colorectal adenomas, which does not align with the patient's diagnosis. |
| [NCT04613596](https://clinicaltrials.gov/study/NCT04613596) | Mirati Therapeutics  | Patient has colorectal cancer, whereas trial only studies non-small cell lung cancer (NSCLC). |
| [NCT05074810](https://clinicaltrials.gov/study/NCT05074810) | Verastem, Inc. | Patient has colorectal cancer, but the trial is for non-small cell lung cancer (NSCLC). |
| ... | ... | *and 15 more* |

## Search Terms Used

| Term | Source | Confidence |
|------|--------|------------|
| KRAS G12C | manual | 1.0 |
| KRASG12C | manual | 0.9 |
| KRAS-G12C | manual | 0.9 |
| colorectal cancer | manual | 1.0 |
| KRAS G12C colorectal cancer | manual | 1.0 |
| KRAS G12C metastatic colorectal cancer | llm | 0.9 |
| KRAS G12C colorectal adenocarcinoma | llm | 0.9 |
| CRC | llm | 0.8 |
| metastatic colorectal cancer | llm | 0.8 |
| KRAS p.G12C | llm | 0.9 |
| KRASp.G12C | llm | 0.8 |
| KRAS-p.G12C | llm | 0.8 |

## Information That Would Improve Matches

The following patient data was not provided but would help refine eligibility assessment:

- **Organ function labs** (hematology, liver, renal) - required by all interventional trials
- **Life expectancy estimate** - many trials require â‰¥3 months
